SQI Diagnostics Announces Patient Enrollment Begins for Its COVID-19 HOME Antibody Test Clinical Study
Submission to U.S. FDA TORONTO, Jan. 25, 2021 /PRNewswire/ - SQI Diagnostics Inc.(the "Company" or "SQI") ( (TSXV: SQD); (OTCQB: SQIDF), a precision medicine company that discovers, develops, and commercializes innovative rapid diagnostic testing for healthcare professionals, patients and consumers worldwide, today announced that patient enrollment began for the Company's clinical study for its direct-to-consumer COVID-19 HOME Antibody Test with the data to be used to support its EUA regulatory submission to the U.S. FDA. The clinical study is being conducted in the United States and will ...
Source: prnewswire.com